Perampanel Monotherapy for Focal and Generalized Epilepsy in Clinical Practice
Authors:
- Yotin ChinvarunYCYotin Chinvarun
- Rafael Toledano DelgadoRDRafael Toledano Delgado
- Alexandra Astner-RohracherAAAlexandra Astner-Rohracher
- Tim WehnerTWTim Wehner
- Manuel ToledoMTManuel Toledo
- Sara MatricardiSMSara Matricardi
- Eugen TrinkaETEugen Trinka
- Manoj MalhotraMMManoj Malhotra
- Oliver ShastriOSOliver Shastri
- Vicente VillanuevaVVVicente Villanueva
Open Access
- 7 February 2023
- journal article
- research article
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2023, 1-12
Abstract
Objectives. To investigate the effectiveness, safety, and tolerability of perampanel (PER) when used as monotherapy to treat focal or generalized epilepsy in everyday clinical practice, using data from the PERMIT study. Methods. PERMIT was a pooled analysis of 44 real-world studies from 17 countries, in which people with focal and generalized epilepsy were treated with PER. This post hoc analysis included people with epilepsy (PWE) from PERMIT who were treated with PER monotherapy at baseline. Retention and effectiveness were assessed after 3, 6, and 12 months. Effectiveness assessments included 50 responder rate and seizure freedom rate (no seizures since at least the prior visit). Safety and tolerability were assessed by evaluating adverse events (AEs) and discontinuation due to AEs. Results. Overall, 268 PWE were treated with PER monotherapy at baseline. Retention was assessed for 168 PWE, effectiveness for 183 PWE, and safety and tolerability for 197 PWE. Retention rates were 91.1, 87.3, and 73.3 at 3, 6, and 12 months, respectively. At 12 months, responder rates were 84.2 overall, 82.9 in PWE with only focal-onset seizures at baseline, and 88.0 in those with only generalized-onset seizures at baseline; corresponding freedom rates were 62.9, 57.7, and 80.0, respectively. AEs were reported for 45.2 of PWE. The most frequently reported AEs (5 of PWE) were dizziness/vertigo (16.8), irritability (11.2), somnolence (9.1), and depression (6.6). Over 12 months, 13.7 discontinued due to AEs. Conclusions. PER was effective when used as monotherapy in clinical practice, particularly in those with generalized-onset seizures, and was generally well tolerated.Keywords
Funding Information
- Eisai
This publication has 38 references indexed in Scilit:
- Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonistActa Neurologica Scandinavica, 2013
- KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsyJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305Epilepsia, 2012
- Adjunctive perampanel for refractory partial-onset seizuresNeurology, 2012
- Adverse antiepileptic drug effects in new-onset seizuresNeurology, 2011
- Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic StrategiesEpilepsia, 2010
- Clinical relevance of patients with epilepsy included in clinical trialsEpilepsia, 2008
- The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- Newly Diagnosed Unprovoked Epileptic Seizures: Presentation at Diagnosis in CAROLE StudyEpilepsia, 2001